Ciliary neurotrophic factor (
CNTF) is a
neurotrophic factor with therapeutic potential for
neurodegenerative diseases. Moreover, therapeutic application of
CNTF reduced
body weight in mice and humans.
CNTF binds to high or low affinity receptor complexes consisting of CNTFR·gp130·LIFR or IL-6R·gp130·LIFR, respectively. Clinical studies of the
CNTF derivative
Axokine revealed intolerance at higher concentrations, which may rely on the low-affinity binding of
CNTF to the IL-6R. Here, we aimed to generate a CNTFR-selective
CNTF variant (CV).
CV-1 contained the single
amino acid exchange R28E. Arg(28) is in close proximity to the CNTFR binding site. Using molecular modeling, we hypothesized that Arg(28) might contribute to IL-6R/CNTFR plasticity of
CNTF. CV-2 to CV-5 were generated by transferring parts of the CNTFR-binding site from
cardiotrophin-like cytokine to
CNTF.
Cardiotrophin-like cytokine selectively signals via the CNTFR·gp130·LIFR complex, albeit with a much lower affinity compared with
CNTF. As shown by immunoprecipitation, all
CNTF variants retained the ability to bind to CNTFR.
CV-1, CV-2, and CV-5, however, lost the ability to bind to IL-6R. Although all variants induced
cytokine-dependent cellular proliferation and STAT3 phosphorylation via CNTFR·gp130·LIFR, only CV-3 induced STAT3 phosphorylation via IL-6R·gp130·LIFR. Quantification of
CNTF-dependent proliferation of CNTFR·gp130·LIFR expressing cells indicated that only
CV-1 was as biologically active as
CNTF. Thus, the CNTFR-selective
CV-1 will allow discriminating between CNTFR- and IL-6R-mediated effects in vivo.